Complicated Skin and Soft Tissue Infections (cSSTIs) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Complicated Skin and Soft Tissue Infections (cSSTIs) Market Outlook

Thelansis’s “Complicated Skin and Soft Tissue Infections (cSSTIs) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Complicated Skin and Soft Tissue Infections treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Complicated Skin and Soft Tissue Infections (cSSTIs) Overview

Skin and soft tissue infections (SSTIs) span many common infectious diseases, often necessitating immediate treatment and hospitalization. These infections display diverse symptoms and involve microbial invasion in increasing severity levels, affecting the epidermis, dermis, superficial fascia, subcutaneous tissues, and muscle. Among these, complicated SSTIs (cSSTIs) are the most severe, infiltrating deeper soft tissues and encompassing infective conditions like cellulitis, ulcer or wound site infections, surgical site infections, significant abscesses, infected burns, skin ulcers, and diabetic foot ulcers. A dominant causative pathogen in cSSTIs is Staphylococcus aureus, an aerobic Gram-positive coccus, which holds critical epidemiological importance. Pseudomonas aeruginosa, Escherichia coli, and Enterococcus spp. have also been recognized as culprits behind cSSTIs. These infections can either involve a single microorganism or a combination, triggering heightened systemic inflammatory responses. Guidelines worldwide offer recommendations for managing cSSTIs, incorporating newer antibiotics into the treatment regimen. The existing gold standard for addressing cSSTIs encompasses incision, drainage, surgical debridement, broad-spectrum antibiotic therapy, and supportive care. It's imperative to consider potential complications associated with cSSTIs during the diagnostic process. These complications may involve lymphadenitis, myositis/necrotizing fasciitis, gangrene, osteomyelitis, bacteremia, endocarditis, septicemia, or sepsis.

• In the United States, the incidence of SSTIs in outpatient settings was estimated at 48.5 cases per 1,000 individuals. Notably, the occurrence of SSTIs was approximately twice that of urinary tract infections (UTIs) and ten times higher than that of pneumonia.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: